Cited by 16Pharmacology and Obesity TreatmentBariatric Surgery and OutcomesObesity and Health Practices

There is no magic bullet for obesity

Open access
Lingvay, Ildiko, Sumithran, Priya, le Roux, Carel W, Cohen, Ricardo V·2023·The Lancet Diabetes & Endocrinology

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(23)00191-2

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Around 10-30% of participants (especially people with T2D) achieved <10% weight loss in clinical trials even with the higher doses of the new pharmacotherapies.

    “Around 10–30% of participants (especially people with T2D) achieved <10% WL in clinical trials even with the higher doses of the new pharmacotherapies [101, 102].”

    From What is the pipeline for future medications for obesity? (2025) · cites this paper as [102]

    The Abstract says that up to 20% of participants in obesity-treatment trials do not experience clinically significant weight loss, supporting the general point that some participants respond poorly. It does not define that outcome as less than 10% weight loss, give a 10–30% range, or say this occurs especially in people with type 2 diabetes or at higher medication doses. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • Obesity is a complex, chronic and progressive disease.

    “As obesity is a complex, chronic and progressive disease, it requires also an individualised and adaptive over time approach [14, 102].”

    From What is the pipeline for future medications for obesity? (2025) · cites this paper as [102]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 5 · Cited by 16

Authors
Lingvay, I., Sumithran, P., le Roux, C. W., & Cohen, R. V.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • Monash University (AU)
  • Hospital Alemão Oswaldo Cruz (BR)
Corresponding author
Cohen, Ricardo V
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2023-08
Volume
11
Issue
8
Pages
541
ISSN
2213-8587 (ISSN-L)
OpenAlex
W4385248365
Cited by
16
References
5
Citations by year
2026: 3 · 2025: 3 · 2024: 7 · 2023: 3
FWCI
2.50
Type
journal article
Language
en
Open access
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Eli Lilly and Company
  • Pfizer
  • Sanofi
  • Mylan
  • Science Foundation Ireland
  • Irish Research Council
  • Novo Nordisk
  • Medical Research Council
  • National Health and Medical Research Council
  • Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Health Professions › Pharmacy › Obesity and Health Practices
Keywords
obesity, obesity pharmacotherapy, weight loss, weight regain, semaglutide, GLP-1 receptor agonists, lifestyle intervention, metabolic surgery, personalized treatment, chronic disease management, media coverage
MeSH terms
Bisacodyl, Humans, Obesity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review